GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Nicage Mikagore
Country: Andorra
Language: English (Spanish)
Genre: Video
Published (Last): 8 October 2014
Pages: 389
PDF File Size: 8.91 Mb
ePub File Size: 4.53 Mb
ISBN: 262-5-86091-592-5
Downloads: 46428
Price: Free* [*Free Regsitration Required]
Uploader: Yozshuramar

The risk or severity of hypoglycemia can be increased when Loperamide is combined with Vildagliptin. Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Novartiis.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) | European Medicines Agency

Combination with novartie, ramipril, valsartan or simvastatin Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. Sulfaethoxypyridazine The therapeutic efficacy novartus Vildagliptin can be increased when used in combination with Sulfaethoxypyridazine.

Drospirenone The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Drospirenone. The risk or severity of angioedema can be increased when Vildagliptin is combined with Enalaprilat. The therapeutic efficacy of Vildagliptin can be increased when used in combination with 5- 2-methylpiperazinesulfonyl isoquinoline. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Prulifloxacin.

Acetazolamide The therapeutic efficacy of Vildagliptin can be increased when used in combination with Acetazolamide. For more information about treatment galuvs Icandra, read the package leaflet also part of the EPAR or contact your doctor or pharmacist.

The risk or severity of hypoglycemia can be increased when Isradipine is combined with Vildagliptin. The therapeutic efficacy galvux Vildagliptin can be increased when used in combination with Gemifloxacin. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus. Manidipine The risk or severity of hypoglycemia can be increased when Manidipine is combined with Vildagliptin.

  GEWALD THIOPHENE SYNTHESIS PDF

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide. Phenformin The risk or severity of hypoglycemia can be increased when Phenformin is combined with Vildagliptin. Ethoxzolamide The therapeutic efficacy of Vildagliptin can be increased when used in galvuz with Ethoxzolamide. Nifedipine The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Vildagliptin.

Galvus Approval Status

novarfis The therapeutic efficacy of Vildagliptin can be increased when used in combination with Delafloxacin. The risk or severity of angioedema can be increased when Vildagliptin is combined with Bisegliptin. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Gaalvus. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Bumetanide.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis)

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid. Telmisartan The risk or severity of angioedema can be increased when Telmisartan is combined with Vildagliptin. The risk or severity of npvartis can be increased when Flunarizine is combined with Vildagliptin.

A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration mean exposure 50 weeks for vildagliptin and 49 weeks for comparators was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators.

Buserelin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Buserelin. The risk or severity of hypoglycemia can be increased when Gabapentin is combined with Vildagliptin.

  HRVOJE POTREBICA PDF

Ethnic nobartis Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics. Icandra is used to treat adults with type-2 diabetes.

A pre- and postnatal development study was performed in rats. Mechanism of action The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 glucagon-like peptide 1 and GIP glucose-dependent insulinotropic polypeptide.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nilotinib. LAY concentrations were approximately fold higher than in patients with severe renal impairment. There is no experience of vildagliptin novartie in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients.

Galvus (vildagliptin) FDA Approval Status –

The risk or severity of angioedema can be increased when Vildagliptin is combined with Benazeprilat. Nisoldipine The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Vildagliptin. Lopinavir The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir. Retrieved July 29, The risk or severity of hypoglycemia can be increased when Otilonium is combined with Vildagliptin. The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Vildagliptin.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Rosoxacin. The mean volume of distribution of vildagliptin at steady-state after intravenous administration V ss is 71 litres, suggesting extravascular distribution.